2017
OP025 Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice
King E, Park K, Pashankar D, Shashidhar H, Sudel B, Eichner S, Chen S, Pratt J, Colletti R, Burlington I. OP025 Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice. Journal Of Crohn's And Colitis 2017, 11: s15-s16. DOI: 10.1093/ecco-jcc/jjx002.024.Peer-Reviewed Original ResearchSteroid-free clinical remissionSteroid-free clinical responseDisease activity indexClinical remissionClinical responseCrohn's diseaseClinical practiceATNF therapyCare visitsDisease patientsShort Pediatric Crohn's Disease Activity IndexAnti-tumor necrosis factor agentsExact testPediatric Crohn's Disease Activity IndexPediatric Crohn's disease patientsCrohn's Disease Activity IndexMultivariable logistic regression analysisConcomitant immunomodulator therapyNecrosis factor agentsPhysician global assessmentRetrospective cohort studyPediatric Crohn's diseaseCrohn's disease patientsNumber of patientsDuration of treatment
2001
Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children
Pashankar D, Bishop W. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. The Journal Of Pediatrics 2001, 139: 428-432. PMID: 11562624, DOI: 10.1067/mpd.2001.117002.Peer-Reviewed Original ResearchConceptsChronic constipationStool frequencyStool consistencyOptimal dosePolyethylene glycol 3350Weekly stool frequencyTreatment of constipationMean effective doseFisher's exact testSignificant adverse effectsStudent's t-testFecal retentionSoft stoolDaily administrationInitial doseMean doseConstipationExact testEffective doseDoseAdverse effectsT-testChildrenTreatmentEfficacy